The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands.

van Hulst, Marinus

The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands. [electronic resource] - Journal of medical economics Jan 2018 - 38-46 p. digital

Publication Type: Comparative Study; Journal Article

1941-837X

10.1080/13696998.2017.1372222 doi


Antithrombins--economics
Atrial Fibrillation--complications
Cohort Studies
Cost-Benefit Analysis--economics
Dabigatran--economics
Female
Humans
Male
Markov Chains
Netherlands
Quality-Adjusted Life Years
Retrospective Studies
Risk Assessment
Thromboembolism--etiology
Treatment Outcome
Vitamin K--administration & dosage